局部化疗和反复手术可以提高胶质母细胞瘤患者的生存率。

A Boiardi, M Eoli, A Pozzi, A Salmaggi, G Broggi, A Silvani
{"title":"局部化疗和反复手术可以提高胶质母细胞瘤患者的生存率。","authors":"A Boiardi,&nbsp;M Eoli,&nbsp;A Pozzi,&nbsp;A Salmaggi,&nbsp;G Broggi,&nbsp;A Silvani","doi":"10.1007/s100720050009","DOIUrl":null,"url":null,"abstract":"<p><p>We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery. In 10 cases the treatment was combined with locoregional chemotherapy (1 mg bleomycin on days 1-2, and 3 mg mitoxantrone on day 3, repeated every 20 days) administered from an Ommaya reservoir. At tumor recurrence, all patients were treated with procarbazine, lomustine and vincristine (PCV); 15 of 54 were reoperated and treated with locoregional chemotherapy. The median time to disease progression (TTP) and overall survival time (ST) for the whole group were 10.8 and 23.1 months, respectively. The ST of the 15 reoperated patients who also received locoregional treatment at disease recurrence was 27.6 months; this was significantly longer than that of patients not reoperated and not treated locally (log-rank p=0.04). The results in our reoperated subgroup support the opinion that a second operation could be suitable if it is part of the whole program of treatment.</p>","PeriodicalId":73522,"journal":{"name":"Italian journal of neurological sciences","volume":"20 1","pages":"43-8"},"PeriodicalIF":0.0000,"publicationDate":"1999-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1007/s100720050009","citationCount":"26","resultStr":"{\"title\":\"Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.\",\"authors\":\"A Boiardi,&nbsp;M Eoli,&nbsp;A Pozzi,&nbsp;A Salmaggi,&nbsp;G Broggi,&nbsp;A Silvani\",\"doi\":\"10.1007/s100720050009\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery. In 10 cases the treatment was combined with locoregional chemotherapy (1 mg bleomycin on days 1-2, and 3 mg mitoxantrone on day 3, repeated every 20 days) administered from an Ommaya reservoir. At tumor recurrence, all patients were treated with procarbazine, lomustine and vincristine (PCV); 15 of 54 were reoperated and treated with locoregional chemotherapy. The median time to disease progression (TTP) and overall survival time (ST) for the whole group were 10.8 and 23.1 months, respectively. The ST of the 15 reoperated patients who also received locoregional treatment at disease recurrence was 27.6 months; this was significantly longer than that of patients not reoperated and not treated locally (log-rank p=0.04). The results in our reoperated subgroup support the opinion that a second operation could be suitable if it is part of the whole program of treatment.</p>\",\"PeriodicalId\":73522,\"journal\":{\"name\":\"Italian journal of neurological sciences\",\"volume\":\"20 1\",\"pages\":\"43-8\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1999-02-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"https://sci-hub-pdf.com/10.1007/s100720050009\",\"citationCount\":\"26\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Italian journal of neurological sciences\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1007/s100720050009\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Italian journal of neurological sciences","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1007/s100720050009","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 26

摘要

我们对54例新诊断为胶质母细胞瘤的患者进行全身化疗(卡莫司定(BCNU) 100mg /m2,顺铂90mg /m2,每6周),术后立即放疗。10例患者联合局部化疗(1 -2天1毫克博来霉素,第3天3毫克米托蒽醌,每20天重复一次),从Ommaya水库中给予。肿瘤复发时,所有患者均应用异丙卡嗪、洛莫司汀和长春新碱(PCV)治疗;54例中15例再次手术并行局部化疗。整个组的中位疾病进展时间(TTP)和总生存时间(ST)分别为10.8个月和23.1个月。15例复发时接受局部治疗的再手术患者的ST为27.6个月;这明显长于未再手术和未局部治疗的患者(log-rank p=0.04)。我们再手术小组的结果支持这样的观点,即如果第二次手术是整个治疗计划的一部分,那么第二次手术是合适的。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Locally delivered chemotherapy and repeated surgery can improve survival in glioblastoma patients.

We treated 54 patients, newly diagnosed for glioblastoma, with systemic chemotherapy (carmustine (BCNU) 100 mg/m2 and cisplatin 90 mg/m2 every 6 weeks) and radiotherapy soon after surgery. In 10 cases the treatment was combined with locoregional chemotherapy (1 mg bleomycin on days 1-2, and 3 mg mitoxantrone on day 3, repeated every 20 days) administered from an Ommaya reservoir. At tumor recurrence, all patients were treated with procarbazine, lomustine and vincristine (PCV); 15 of 54 were reoperated and treated with locoregional chemotherapy. The median time to disease progression (TTP) and overall survival time (ST) for the whole group were 10.8 and 23.1 months, respectively. The ST of the 15 reoperated patients who also received locoregional treatment at disease recurrence was 27.6 months; this was significantly longer than that of patients not reoperated and not treated locally (log-rank p=0.04). The results in our reoperated subgroup support the opinion that a second operation could be suitable if it is part of the whole program of treatment.

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信